ROVI and the EIB agreement

ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies


No votes yet
 
Relacionados
ROVI reports operating revenue growth of 12% and net profit growth of 53%
Laboratorios Farmacéuticos Rovi, S.A. (BME: ROVI), compañía farmacéutica paneuropea especializada y dedicada a la investigación,...
6 min
24/11/2020